GE Healthcare Technologies Inc

GE Healthcare Technologies Inc(GEHC)股票分析

$70.350

+1.935 (+2.75%)收盤時

Loading chart…
最高
70.990
開盤
69.800
成交量加權均價
70.28
成交量
3.75M
市值
35.98B
最低
69.500
成交金額
263.41M
企業價值/稅息折舊攤銷前利潤(TTM)
9.91

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

AI 分析 of GE Healthcare Technologies Inc (GEHC)

買進

GE Healthcare Technologies Inc is a good buy right now due to its current price of $65.74, which is below the analyst price targets of $85 and $93 from Barclays and Needham, respectively. The company has shown a positive trend with a 5-day change of +2.26% and a recent dividend increase of 14%, reflecting strong financial health. However, the main risk is the year-to-date change of -20.62%, indicating potential volatility in the stock's performance.

估值指標

GE Healthcare Technologies Inc(GEHC)目前預期本益比為 12.12,5 年平均預期本益比為 17.48。

預期本益比

嚴重低估
5 年均值 P/E
17.48
目前P/E
12.12
高估
19.91
低估
15.05

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
11.34
目前EV/EBITDA
9.91
高估
12.85
低估
9.83

預期股價營收比

合理
5 年均值 P/S
1.67
目前P/S
1.40
高估
1.95
低估
1.40

Alphio AI 對 GEHC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%GEHC

$83.18

情境價格

基

基準

基準 · 50%GEHC

$81.20

情境價格

悲

悲觀

悲觀 · 25%GEHC

$74.35

情境價格

持有 GEHC 的大戶

H

Hotchkis and Wiley Capital Management, LLC

+ 持有GEHC

+8.90%

3個月報酬率

N

NewEdge Advisors, LLC

+ 持有GEHC

+7.34%

3個月報酬率

S

Salem Investment Counselors, Inc.

+ 持有GEHC

+6.48%

3個月報酬率

B

Barrow, Hanley, Mewhinney & Strauss, LLC

+ 持有GEHC

+5.78%

3個月報酬率

L

Letko, Brosseau & Associates Inc.

+ 持有GEHC

+3.87%

3個月報酬率

D

Dodge & Cox

+ 持有GEHC

+3.87%

3個月報酬率

事件時間軸

2026-10-15 (ET)

08:30:00

GE HealthCare Announces MINItrace Magni Achieves CE Mark

2026-10-05 (ET)

16:30:00

Nasdaq Rises Nearly 300 Points as Market Digests Jobs Report

12:30:00

Nasdaq Rises Nearly 200 Points, Led by Tech Stocks

08:30:00

GE HealthCare Acquires SOFIE Biosciences for $945M

資訊

GEHC 常見問題 —— 由 Alphio AI 解答

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

GE Healthcare Technologies Inc is a good buy right now due to its current price of $65.74, which is below the analyst price targets of $85 and $93 from Barclays and Needham, respectively. The company has shown a positive trend with a 5-day change of +2.26% and a recent dividend increase of 14%, reflecting strong financial health. However, the main risk is the year-to-date change of -20.62%, indicating potential volatility in the stock's performance.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易